Neuraminidase inhibitors as anti-influenza virus agents

Antiviral Chemistry and Chemotherapy

Volumn 10, Issue 4, 1999, Pages 141-154

  Kim, Choung U ^a   Chen, Xiaowu ^a   Mendel, Dirk B ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

GS 4104; Influenza; Inhibitors; Neuraminidase; Zanamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ANTIVIRUS AGENT; OSELTAMIVIR; SIALIC ACID; SIALIDASE INHIBITOR; VIRUS SIALIDASE; ZANAMIVIR;

DRUG DESIGN; DRUG MECHANISM; INFLUENZA; INFLUENZA VIRUS; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION;

EID: 0032796258     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029901000401     Document Type: Review

References (56)

1. Bamford MJ, Pichel JC, Husman W, Patel B, Storer R & Weir NG (1995) Synthesis of 6-, 7- and 8 -carbon sugar analogues of potent anti-influenza 2, 3-dihydro-2, 3-dideoxy-N-acetylneuramic acid derivatives. Journal of the Chemical Society, Perkin Transcripts I: 1181-1187.
2. Blick TJ, Tiong T, Sahasrabudhe A, Varghese JN, Colman PM, Hart GJ, Bethell RC & McKimm-Breschkin JL (1995) Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2En. Virology 214:475-484.
3. Bossart-Whitaker P, Carson M, Babu YS, Smith CD, Laver WG & Air GM (1993) Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy-2,3-dehydro-N-acetyl neuraminic acid. Journal of Molecular Biology 232:1069-1083.
4. Burmeister WP, Ruigrok RW & Cusack S (1992) The 2.2 Å resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO Journal 11:49-56.
5. Chand P, Babu YS, Bantia S, Chu N, Cole B, Kotian PL, Laver WG, Montgomery JA, Pathak VP, Petty SL, Shrout DP, Walsh DA & Walsh GM (1997) Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design. Journal of Medicinal Chemistry 40:4030-4052.
6. Colacino JM, Chirgadze NY, Garman E, Murti KG, Loncharich RJ, Baxter AJ, Staschke KA & Laver WG (1997) A single sequence change destabilizes the influenza virus neuraminidase tetramer. Virology 236:66-75.
7. Colman PM (1994) Influenza virus neuraminidase: structure, antibodies and inhibitors. Protein Science 3:1687-1696.
8. Couch RB, Keitel W, Cate TR, Quarles JA, Taber LA & Glezen WP (1996) Prevention of influenza virus infections by current inactivated influenza virus vaccines. In Options for the Control of Influenza III, pp. 97-106. Edited by LE Brown, AW Hampson & RG Webster. Amsterdam: Elsevier.
9. Dowle MD & Howes PD (1998) Recent advances in sialidase inhibitors. Expert Opinions on Therapeutic Patents 8:1461-1478.
10. Eisenberg EJ, Bidgood A & Cundy KC (1997) Penetration of GS 4071, a novel influenza inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug, GS 4104. Antimicrobial Agents and Chemotherapy 41: 1949-1952.
11. Goto H, Bethell RC & Kawaoka Y (1997) Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 238:265-272.
12. Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR & Webster RG (1996) Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2En. Journal of Virology 70:1818-1827.
13. Gubareva LV, Robinson MJ, Bethell RC & Webster RG (1997) Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2En. Journal of Virology 71:3385-3390.
14. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC & Webster RG (1998) Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. Journal of Infectious Diseases 178:1257-1262.
15. Hay AJ, Wolstenholme AJ, Skehel JJ & Smith MH (1985) The molecular basis of the specific anti-influenza action of amantadine. EMBO Journal 4:3021-3024.
16. Hayden FG & Couch RB (1992) Clinical and epidemiological importance of influenza A viruses resistant to amantadine and rimantadine. Reviews in Medical Virology 2:89-96.
17. Hayden FG & Rollins BS (1997) In vitro activity of the neuraminidase inhibitor GS4071 against influenza viruses. Antiviral Research 34:A86, Abstract 159
18. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O & Wightman K (1997) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. New England Journal of Medicine 337:874-880.
19. Hayden FG, Atmar R, Schilling M, Johnson C, Portez D, Parr D, Huson L, Wand P and Mills R (1998a) Safety and efficacy of oral GS 4104 in longterm prophylaxis of natural influenza. Journal of the American Medical Association 281: In press
20. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD & Hussey EK (1998b) Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. Journal of the American Medical Association 276:295-299.
21. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P & Straus SE (1998c) Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized, controlled trials for prevention and treatment. Journal of the American Medical Association 281: In press
22. Holzer CT, von Itzstein M, Jin B, Pett MS, Stewart WP & Wu WY (1993) Inhibition of sialidase from viral, bacterial and mammalian sources by analogues of 2-deoxy-2, 3-didehydro-N-acetylneuramic acid mofified at the C-4 position. Glycoconjugates Journal 10:40-44.
23. Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY, Laver WG & Stevens RC (1997) Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. Journal of the American Chemical Society 119:681-690.
24. Kim CU, Lew W, Williams MA, Wu H, Zhang L, Chen X, Escarpe PA, Mendel DB, Laver WG & Stevens RC (1998) Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. Journal of Medicinal Chemistry 41:2451-2460.
25. Klenk H-D & Rott R (1988) The molecular biology of influenza virus pathogenicity. Advances in Virus Research 34:247-280.
26. 3-Carba isosteres of a carbocyclic influenza neuraminidase inhibitor (3R, 4R, 5S)-4-acetamido-5-amino-3-propoxy-1-cyclohexene-1-carboxylic acid. Bioorganic and Medicinal Chemistry Letters 7:1843-1846.
27. 3-Aza carbocyclic infleunza neuraminidase inhibitors: synthesis and inhibitory activity. Bioorganic and Medicinal Chemistry Letters 8:3321-3324.
28. Li W-X, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew W, Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS & Mendel DB (1998) Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrobial Agents and Chemotherapy 42:647-653.
29. Lipinski CA, Lombardo F, Dominy BW & Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 23:3-25.
30. Liu C, Eichelberger MC, Compans RW & Air GM (1995) Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly or budding. Journal of Virology 69:1099-1106.
31. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, Tiong T, Marshall D, Hart GJ, Bethell RC & Penn CR (1996a) Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2En and 4-guanidino-Neu5Ac2En. Antimicrobial Agents and Chemotherapy 40:40-46.
32. McKimm-Breschkin JL, McDonald M, Blick TJ & Colman PM (1996b) Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology 225:240-242.
33. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, Hart GJ, Bethell RC & Varghese JN (1998) Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. Journal of Virology 72:2456-2462.
34. Meanwell NA & Krystal M (1996) Taking aim at a moving target -inhibitors of influenza virus. Part 2: Viral replication, packaging and release. Drug Discovery Today 1:388-397.
35. Meindl P, Bodo G, Palese P, Schulman J & Tuppy H (1974) Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 58:457-463.
36. Mendel DB & Roberts NA (1998) In vitro and in vivo efficacy of influenza neuraminidase inhibitors. Current Opinion in Infectious Diseases 11:727-732
37. Mendel DB & Sidwell RW (1998) Influenza virus resistance to neuraminidase inhibitors. Drug Resistance Updates 1:184-189.
38. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, Sweet C, Jakeman KJ, Merson J, Lacy SA, Lew W, Williams MA, Zhang L, Chen MS, Bischofberger N, Kim CU (1998) Oral administration of a prodrug of the influenza neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrobial Agents and Chemotherapy 42:640-646.
39. Monto AS & Arden NH (1992) Implications of viral resistance to amantadine in control of influenza A. Clinical Infectious Diseases 15:362-367.
40. Palese P, Tobita K, Ueda M & Compans RW (1974) Characterization of temperature sensitive influenza virus mutants. Virology 61:397-410.
41. Palese P & Compans RW (1976) Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. Journal of General Virology 33:159-163.
42. Penn CR, Barnett JM, Bethell RC, Fenton R, Gearing KL, Healy N & Jowett AJ (1996). Selection of influenza virus with reduced sensitivity in vitro to the neuraminidase inhibitor GG167 (4-guanidino-Neu5Ac2en): changes in haemagglutinin may compensate for loss of neuraminidase activity. In Options for the Control of Influenza III, pp. 735-740. Edited by LE Brown, AW Hampson & RG Webster. Elsevier: Amsterdam, The Netherlands.
43. Ryan DM, Ticehurst J, Dempsey MH & Penn CR (1994) Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrobial Agents and Chemotherapy 38:2270-2275.
44. Ryan DM, Ticehurst J & Dempsey MH (1995) GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrobial Agents and Chemotherapy 39:2583-2584.
45. Sahasrabudhe A, Blick T & McKimm-Breschkin J (1996). Influenza virus variants resistant to GG167 with mutations in the haemagglutinin. In Options for the Control of Influenza III, pp. 748-752. Edited by LE Brown, AW Hampson & RG Webster. Australia: Elsevier Science B.V.
46. Sidwell RW, Huffman JH, Barnard DL, Bailey KW, Wong M-H, Morrison A, Syndergaard T & Kim CU (1998) Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza neuraminidase inhibitor. Antiviral Research 37:107-120.
47. Sollis SL, Smith PW, Howes PD, Cherry PC & Bethell RC (1996) Novel inhibitors of influenza sialidase related to GG167. Bioorganic and Medicinal Chemistry Letters 6:1805-1808.
48. Staschke KA, Colacino JM, Baxter AJ, Air GM, Bansal A, Hornback WJ, Munroe JE &, Laver WG (1995) Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2En. Virology 214:642-646.
49. Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, Wu H, Kim CU & Mendel DB (1998) Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrobial Agents and Chemotherapy 42:3234-3241.
50. Taylor NR & von Itzstein M (1994) Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. Journal of Medicinal Chemistry 37:616-624.
51. Taylor, NR, Cleasby A, Singh O, Skarzynski T, Wonacott AJ, Smith PW, Sollis SL, Howes PD, Cherry PC, Bethell R, Colman P & Varghese J (1998) Dihydropyran carboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxarnides and sialidase from influenza virus types A and B. Journal of Medicinal Chemistry 41:798-807.
52. Tedrzejas MJ, Singh S, Brouilette WJ, Laver GW, Air GM & Luo M (1995) Structure of aromatic inhibitors of influenza virus neuraminidase. Biochemistry 34:3144-3151.
53. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA & Colman PM (1992) The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14:327-332.
54. Varghese JN, Smith PW, Sollis SL, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL & Colman PM (1998) Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6:735-746.
55. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Phan TV, Smyth ML, White HF, Oliver SW, Colman PM, Varghese JN, Ryan DM, Wood JM, Bethell RC, Hotham VJ, Cameron JM & Penn CR (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423.
56. Williams MA, Bischofberger N, Swaminathan S & Kim, CU (1995) Synthesis and influenza neuraminidase inhibitory activity of aromatic analogues of sialic acid. Bioorganic and Medicinal Chemistry Letters 5:2251-2254.